Sustained reductions in inflammatory markers seen with novel antibody drug Medical XpressMonoclonal antibody targeting interleukin-6 achieves sustained reductions in inflammation biomarkers through six months Medical XpressA Novartis drug cut inflammation. Can it improve heart outcomes? STAT#ESC26: Novartis pushes ahead with its IL-6 inhibitor despite Novo’s failure Endpoints NewsPacibekitug Sustains Inflammatory Biomarker Reduction in CKD in TRANQUILITY Trial HCPLive
Sustained reductions in inflammatory markers seen with novel antibody drug Medical XpressMonoclonal antibody targeting interleukin-6 achieves sustained reductions in inflammation biomarkers through six months Medical XpressA Novartis drug cut inflammation. Can it improve heart outcomes? STAT#ESC26: Novartis pushes ahead with its IL-6 inhibitor despite Novo’s failure Endpoints NewsPacibekitug Sustains Inflammatory Biomarker Reduction in CKD in TRANQUILITY Trial HCPLive
